Company Novartis AG

Equities

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange 11:30:23 2024-02-23 am EST 5-day change 1st Jan Change
91.63 CHF +1.17% Intraday chart for Novartis AG +3.61% +7.97%

Business Summary

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by family of products as follows:

- pharmaceutical products (81.7%): used to treat cardiovascular, respiratory, and dermatological diseases, gastrointestinal disorders, cancers, central nervous system disorders, hormone imbalances, etc.;

- generic drugs (18.3%; Sandoz).

Net sales are distributed geographically as follows: Europe (36.5%), the United States (34.9%), Asia/Africa/Australasia (20.9%), Canada and Latin America (7.7%).

Number of employees: 76,057

Sales per Business

CHF in Million2022Weight2023Weight Delta
Established Brands
30.0 %
- - 12,238 30.0 % -
Oncology
29.9 %
- - 12,213 29.9 % -
Immunology
17.2 %
- - 7,008 17.2 % -
Cardiovascular, Renal and Metabolic
14.1 %
- - 5,743 14.1 % -
Neuroscience
8.9 %
- - 3,633 8.9 % -

Sales per region

CHF in Million2022Weight2023Weight Delta
United States
39.5 %
16,860 34.9 % 16,139 39.5 % -4.28%
Europe
18.9 %
10,469 21.7 % 7,704 18.9 % -26.41%
Asia/Africa/Australasia
9.1 %
4,975 10.3 % 3,700 9.1 % -25.63%
Germany
7.4 %
4,086 8.5 % 3,026 7.4 % -25.94%
China
7.2 %
2,987 6.2 % 2,936 7.2 % -1.73%
Canada and Latin America
7.0 %
3,709 7.7 % 2,854 7.0 % -23.04%
Japan
4.2 %
2,106 4.4 % 1,729 4.2 % -17.90%
France
3.8 %
2,156 4.5 % 1,572 3.8 % -27.09%
Switzerland
2.9 %
926 1.9 % 1,175 2.9 % +26.88%

Managers

Managers TitleAgeSince
Chief Executive Officer 48 04-12-31
Director of Finance/CFO 59 02-12-31
Chief Tech/Sci/R&D Officer 62 22-05-15
Chief Operating Officer 57 17-03-31
Compliance Officer 56 18-11-30
Public Communications Contact 63 03-12-31
Corporate Officer/Principal - 13-07-31
Comptroller/Controller/Auditor 61 22-04-30
Corporate Officer/Principal - -
Human Resources Officer 56 21-08-31

Members of the board

Members of the board TitleAgeSince
Director/Board Member 62 12-12-31
Director/Board Member 65 20-02-27
Chairman 68 12-12-31
Director/Board Member 60 23-03-06
Director/Board Member 63 20-02-27
Director/Board Member 59 15-12-31
Director/Board Member 65 12-12-31
Director/Board Member 66 14-12-31
Director/Board Member 68 19-02-27
Director/Board Member 63 17-02-27

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 2,277,477,752 1,965,291,633 ( 86.29 %) 233,443,766 ( 10.25 %) 86.29 %

Shareholders

NameEquities%Valuation
227,771,554 10.00 % 23 737 M CHF
Sandoz Family Foundation
3.914 %
89,135,960 3.914 % 9 289 M CHF
UBS Asset Management Switzerland AG
2.677 %
60,962,889 2.677 % 6 353 M CHF
Novartis Foundation For Employee Participation
2.100 %
47,834,052 2.100 % 4 985 M CHF
Universal-Investment-Gesellschaft mbH (Invt Mgmt)
0.2895 %
6,593,896 0.2895 % 687 M CHF
State Street Global Advisors Ltd.
0.2337 %
5,321,875 0.2337 % 555 M CHF
MFS International (UK) Ltd.
0.1716 %
3,908,976 0.1716 % 407 M CHF
UBS AG (Investment Management)
0.1713 %
3,902,170 0.1713 % 407 M CHF
La Mondiale SAM (Investment Portfolio)
0.1707 %
3,888,630 0.1707 % 405 M CHF
Sjunde AP-fonden
0.1548 %
3,526,412 0.1548 % 368 M CHF
NameEquities%Valuation
Dodge & Cox
0.5781 %
13,165,538 0.5781 % 1 362 M CHF
PRIMECAP Management Co.
0.5667 %
12,905,697 0.5667 % 1 335 M CHF
Eaton Vance Management
0.3114 %
7,092,253 0.3114 % 734 M CHF
Dimensional Fund Advisors LP
0.2669 %
6,078,175 0.2669 % 629 M CHF
Loomis, Sayles & Co. LP
0.2639 %
6,009,900 0.2639 % 622 M CHF
Fiduciary Trust Company International
0.2598 %
5,915,750 0.2598 % 612 M CHF
U.S. Trust Company of Delaware
0.2309 %
5,258,331 0.2309 % 544 M CHF
Wellington Management Co. LLP
0.2084 %
4,746,599 0.2084 % 491 M CHF
Wells Fargo Bank NA
0.1754 %
3,994,934 0.1754 % 413 M CHF
The Ayco Co. LP
0.1553 %
3,535,902 0.1553 % 366 M CHF
NameEquities%Valuation
Dimensional Fund Advisors Ltd.
0.000475 %
43,231 0.000475 % 2 M CHF
NameEquities%Valuation
LUKB Expert Fondsleitung AG
-
64,694 - 7 M CHF
ATP Fondsmaeglerselskab A/S
-
46,082 - 5 M CHF
Swiss Rock Asset Management AG
-
19,614 - 2 M CHF
Niederer & Partners AG
-
5,300 - 558 945 CHF
Liontrust Portfolio Management Ltd.
-
474 - 49 989 CHF

Holdings

NameEquities%Valuation
227,771,554 10.00% 23,736,991,562 $
18,524,209 4.30% 643,494,157 $
17,450,680 70.68% 207,711,256 $
2,153,526 3.60% 38,591,186 $
2,642,762 6.55% 22,912,747 $
1,713,521 4.68% 22,275,773 $
12,307,692 8.15% 20,553,846 $
5,908,089 6.18% 20,323,826 $
1,739,130 4.78% 8,413,354 $
12,407,440 10.18% 4,677,605 $

Company contact information

Novartis AG

Lichtstrasse 35

4056, Basel

+41 61 324 1111

http://www.novartis.com
address Novartis AG(NOVN)

Group companies

NameCategory and Sector
Pharmaceuticals: Major
Investment Managers
Pharmaceuticals: Major
Investment Managers
Pharmaceuticals: Major
Finance/Rental/Leasing
Novartis Finance SA
Finance/Rental/Leasing
Pharmaceuticals: Major
Pharmaceuticals: Major

Sales per Business

Sales per region

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
104 USD
Average target price
109.5 USD
Spread / Average Target
+5.32%
Consensus
1st Jan change Capi.
+7.97% 213 B $
+32.01% 693 B $
+21.62% 550 B $
+3.25% 390 B $
+18.74% 328 B $
+14.92% 315 B $
-4.95% 212 B $
-3.58% 201 B $
-3.58% 157 B $
+0.42% 155 B $
Other Pharmaceuticals
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW